investigated the effects of AML-derived EVs on T cell subsets by an in vitro approach to study the effects of EVs derived from the human AML cell line MOLM-14 cells on CD4+, CD4+CD39+, and CD8+ T cell subsets from healthy individuals; the results showed that tumor-derived EVs modulate T cell responses by upregulating immune processes, such as immunosuppression and oncogenic gene expression (57). This evidence concerns the gene ENTPD1 and acute myeloid leukemia.